ReviewDiscover nano2026
Topical strategies for antimicrobial delivery of peptide medicines for the management of chronic wounds.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic wounds remain difficult to manage because persistent infection, biofilm formation, and antimicrobial resistance limit the effectiveness of conventional antibiotics. Antimicrobial peptides (AMPs) have emerged as promising therapeutic alternatives because they combine broad-spectrum membrane activity with quorum-sensing interference and immunomodulatory effects but generally impose a lower resistance burden than single-target antibiotics do. This review examines topical delivery systems designed to improve AMP stability, local bioavailability, targeted release, and residence time within the wound microenvironment. Hydrogels and films provide moist, biocompatible matrices for localized and sustained peptide release, including alginate-based systems with activity against Pseudomonas aeruginosa biofilms. Nanoparticle platforms, including lipid, metallic, liposomal, and micellar systems, can protect AMPs from enzymatic degradation and generate depot-like release profiles against drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus. Biopolymer scaffolds, microneedles, and stimuli-responsive carriers activated by pH, reactive oxygen species, temperature, light, or ultrasound provide spatiotemporal control of AMP deployment in infected wounds. These strategies are particularly relevant to chronic diabetic wounds, where delayed healing, persistent inflammation, and biofilm burden frequently coexist. Smart design elements, including extracellular matrix-mimetic nanofibers, integrated pH and cytokine sensors, cyclic peptides, and dendrimers, further extend AMP function by linking antimicrobial activity with tissue regeneration and wound monitoring. Preclinical studies report accelerated closure, reduced inflammatory burden, and biofilm disruption, but clinical translation remains limited by manufacturing scalability, dose-dependent cytotoxicity, sterilization stability, and limited human validation. Overall, next-generation topical AMP delivery systems offer a rational route to combine infection control with regenerative wound repair while reducing the reliance on conventional antibiotics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.